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ABSTRACT ÖZ
Hepatitis B virus (HBV) infection is a major health problem 
worldwide. HBV reactivation is associated with high mortality rates 
in hematopoietic stem cell transplantation (HSCT) and, prophylactic 
antiviral treatment is suggested to prevent this phenomenon. 
However, the duration of antiviral treatment in HSCT patients is 
not fully defined and the time of immune recovery is considered 
the best parameter for a drug to be safely interrupted. We aimed 
to present a case of hepatitis B reactivation after cessation of 
one-year prophylactic tenofovir treatment in a anti-hepatitis B core 
immunoglobulin G-positive patient who received allogenic HSCT 
treatment for chronic lymphocytic leukemia.
Keywords: Hepatitis B reactivation, tenofovir, hematopoietic stem 
cell transplantation
Hepatit B virüs (HBV) enfeksiyonu dünya çapında önemli bir sağlık 
sorunudur. Hematopoietik kök hücre transplantasyonunda (HSCT) HBV 
reaktivasyonu yüksek mortalite oranları ile ilişkilidir ve bu durumun 
önlenmesi için profilaktik antiviral tedavi önerilmektedir. Bununla 
birlikte, HSCT hastalarında verilecek antiviral tedavinin süresi tam olarak 
tanımlanmamıştır ve antiviral tedavinin sonlandırılmasında bağışıklık 
kazanım zamanı en güvenilir parametre olarak kabul edilmektedir. Biz 
burada, kronik lenfositik lösemi tanısıyla allojenik HSCT tedavisi uygulanan 
anti-hepatit B core immünoglobulin G pozitif bir hastada transplant sonrası 
verilen bir yıl profilaktik tenofovir tedavisinin kesilmesi sonrasında ortaya 
çıkan bir hepatit B reaktivasyonu olgusunu sunmayı amaçladık.
Anahtar Kelimeler: Hepatit B reaktivasyonu, tenofovir, 
hematopoietik kök hücre transplantasyonu
Introduction
The natural course of hepatitis B virus (HBV) infection is 
determined through the interaction between viral replication and the 
host immune response. HBV reactivation is defined as elevation of 
the viral DNA level or alteration of the hepatitis B surface antigen 
(HBsAg) seroconversion status. In HBsAg carriers, it is characterised 
by either increase in HBV DNA level by >1 log (10 fold) or HBV DNA 
turning positive. Other than this, in HBsAg- and antibody to hepatitis 
B core antigen (anti-HBc)+ patients, reverse seroconversion of HBsAg 
from negative to positive is defined as reactivation (reappearance of 
HBsAg with or without increased liver enzymes) (1,2). Patients 
undergoing allogeneic hematopoietic stem cell transplantation 
(HSCT) are considered high risk for HBV reactivation (3), with a 
mortality rate of up to 40%. Third-generation antiviral drugs (entecavir 
or tenofovir) are recommended for patients with HBsAg or anti-HBc 
immunoglobulin (Ig) G-positive haematologic patients regardless of 
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HBV DNA levels (4,5). Antiviral therapy initiated simultaneously with 
or prior to immunosuppressive therapy can reduce the risk of HBV 
reactivation. Many studies have evaluated the efficacy of prophylactic 
therapy (6,7); however, the duration of antiviral treatment in HSCT 
patients is not fully defined. We aimed to present a case of hepatitis 
B reactivation after cessation of one-year prophylactic tenofovir 
treatment in an anti-HBc IgG-positive patient who received allogenic 
HSCT treatment for chronic lymphocytic leukemia.
Case
A 64-year-old male patient was admitted to our clinic with 
the complaints of fatigue, nausea, vomiting, and jaundice. His 
complaints began 3 days ago and gradually increased. Anti-HBc 
IgG positivity was detected 16 months ago with the screening 
tests performed before the immunosuppressive treatment. The 
patient was treated with 2 cycles of rituximab and then allogenic 
HSCT was performed for chronic lymphocytic leukemia. He was 
administered cyclosporin 5 mg/kg for six months after HSCT, then 
the dose was reduced and stopped at the end of the one-year 
treatment. During the rituximab period, he was administered 
prophylactic tenofovir 245 mg/day and for one year following 
HSCT treatment. Tenofovir treatment was stopped three months 
ago (one year after HSCT). He did not have any chronic diseases 
and there was no any liver disease in his family history. On 
physical examination, his sclera and the skin were icteric. His 
laboratory findings were as follows: alanine aminotransferase 
(ALT): 1365 U/L, aspartate aminotransferase (AST): 1066 U/L, 
alkaline phosphatase (ALP): 276 U/L, gamma-glutamyl transferase 
(GGT): 108 U/L, total biluribin: 18.44 mg/dL, direct biluribin: 9.46 
mg/dL, international normalized ratio (INR): 1.40, albumin: 4.1 g/
dL, white blood cell count: 5.690/uL, hemoglobin level: 15 g/dL, 
and platelet count: 67.000/uL. Alpha feto-protein level was not 
measured. The kidney function tests and electrolyte levels were 
normal. HBsAg, anti-HBc IgM, anti-HBc IgG, and anti- hepatitis B 
e (HBe) were found to be positive whereas HBe antigen (HBeAg) 
and delta antigen were found negative. HBV DNA level was 
486.336.116 IU/mL. Other serological markers of viral infection 
(such as Epstein-Barr virus, cytomegalovirus, herpes simplex 
virus, hepatitis A, C, and E viruses) were all negative. Abdominal 
ultrasonography showed normal liver.
When the patient’s tests performed prior to tenofovir withdrawal 
were investigated, it was seen that anti-HBc IgG was positive and 
HBsAg was negative. Liver function tests were normal when he 
received chemotherapy and one year post-HSCT. The treatment of 
tenofovir 245 mg was started again with the diagnosis of hepatitis 
B reactivation. After 2 months of tenofovir treatment his laboratory 
findings were found to be: ALT: 48 U/L, AST: 76 U/L, ALP: 230 
U/L, GGT: 305 U/L, total bilirubin: 4.19 mg/dL, direct bilirubin: 1.60 
mg/dL, INR: 1.12, albumin: 3.2 g/dL, and HBV DNA 17.932 IU/mL 
(Table 1).
Informed consent for publication was obtained from the 
patient.
Discussion
Patients with malignancy, autoimmune diseases or HSCT 
with serologic evidence of HBV infection (HBsAg or anti-HBc 
IgG-positive) are at risk for HBV reactivation if they receive 
immunosuppressive therapy. Reactivation of HBV infection in the 
setting of chemotherapy and immunosuppression is associated 
with significant morbidity and mortality (8).
Hepatitis B reactivation appears to correlate with the 
level of immunosuppressive potency of the chemotherapy 
administered as well as with the use of concomitant steroids 
(9). The rate of HBV reactivation has been reported to be as high 
as 70% among HBsAg-positive individuals receiving HSCT or 
anti CD20 treatment (2). The risk of HBV reactivation depends 
on many factors including the virological and serological status 
of the infected patient, immunosuppressive potency of the 
therapy received, underlying disease, male sex, younger age, 
HBsAg, HBeAg and/or HBV DNA positivity at the baseline (10). 
HBsAg-positive patients are more likely to experience HBV 
reactivation than HBsAg-negative and anti-HBc-positive patients 
(11). Although the risk is lower, isolated anti-Hbc-positive 
patients still carry a definite risk of reactivation (12). However, 
there is limited evidence that the presence of anti-HBs is 
protective against HBV reactivation. An earlier study on 29 
lymphoma patients reported no HBV reactivation in any of the 
patients (0/10) whose anti-HBs titer was higher than 100 IU/mL 
and low anti-HBs titer was independently associated with HBV 
reactivation (13). In patients receiving HSCT, anti-HBs titer of 
the donor was associated with a reduction in HBV reactivation 
risk. These findings have not yet been confirmed (14). Severe 
hepatitis can develop in up to 30-50 percent of patients with 
HBV reactivation (2,15), therefore, antiviral therapy should be 
initiated in these patients.
According to the American Gastroenterological Association 
guidelines, high-risk patients should be treated with 
prophylactic antiviral therapy prior to or concurrently with the 
immunosuppressive treatment. Moderate-risk patients can be 














ALT U/L 26 30 1365 48
AST U/L 30 18 1066 76
Total biluribin 
mg/dL
0.45 0.86 18.44 4.19
INR 1 0.98 1.40 1.21
HBsAg - - + +
Anti-HBc IgG + + + +
Anti-HBs - - - -
HBe Ag - - - -
Anti-HBe + + + +
Anti-HBc IgM - +
HBV DNA IU/mL - - 486.336.116 17.932
HSCT: Hematopoietic stem cell transplantation, HBV: Hepatitis B virus, 
ALT: Alanine aminotransaminase, AST: Aspartate aminotransferase, INR: 
International normalized ratio, HBsAg: Hepatitis B surface antigen, HBc: 
Hepatitis B core antigen, IgG: Immunoglobulin G, HBs: Hepatitis B surface, 
HBe: Hepatitis B e, IgM: Immunoglobulin M
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treated with antiviral prophylaxis or monitored closely (16). Antiviral 
prophylaxis is not recommended for low-risk patients and there 
are no recommendations about monitoring in untreated patients. 
The European Association for the Study of the Liver (EASL) 
recommends antiviral prophylaxis for HBsAg-positive patients and 
for HBsAg-negative/anti-HBc-positive patients receiving rituximab, 
bone marrow or stem cell transplantation (17). Regarding HBsAg-
positive patients, most treatment guidelines such as the American 
Association for the Study of Liver Diseases (initiation of antivirals at 
the onset of immunosupression), and the Asian Pacific Association 
for the Study of the Liver guidelines (initiation of antivirals one 
week prior to chemotherapy) recommend prophylactic treatment 
(18,19).
Seto et al. (20) published a prospective study investigating the 
course of 62 HBsAg-negative, anti-HBc-positive HSCT recipients. 
The 2-year cumulative HBV DNA detectability rate was 40.8%, 
occurring at a median of 44 weeks, and entecavir successfully 
suppressed HBV DNA to undetectable levels, with no cases 
developing biochemical hepatitis.
Entecavir or tenofovir can be used in the treatment of HBV 
reactivation (21). The success rate of early antiviral therapy is 
high in patients with acute flare (22). The EASL recommends ALT 
and HBV DNA testing every 1-3 months during monitoring and 
treatment upon any evidence of HBV reactivation (23).
Patients with positive HBV serologic markers receiving 
immunosuppressive therapy or HSCT are at high risk for reactivation. 
As seen in our case, 12 months of prophylaxis treatment may not 
be sufficient for patients undergoing allogeneic HSCT. Current 
guidelines recommend that the duration of prophylaxis after HSCT 
and high-risk immunosuppressive therapy should be 12-18 months 
(24). However, the risk of HBV reactivation in HSCT can persist for 
several years after transplantation due to the long delays in the 
immune reconstitution.
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